Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus VIRAC REX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus VIRAC REX.
EMTRICITABINE vs VIRAC REX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
VirAcRex is a direct-acting antiviral that inhibits the viral RNA-dependent RNA polymerase (NS5B) by acting as a chain terminator, thereby blocking viral replication.
200 mg orally once daily, typically in combination with other antiretroviral agents.
300 mg orally once daily with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life: 2.5-3.5 hours; clinical context: requires thrice-daily dosing to maintain therapeutic levels.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Renal: 30-40% unchanged; biliary/fecal: 50-60% as metabolites; <10% in feces as parent drug.
Category C
Category C
Antiretroviral, NRTI
Antiretroviral
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."